21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...
22:44 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy In vitro , mouse and rat studies identified a benzenesulfonamide-based CAII inhibitor that could help treat epilepsy. Chemical synthesis of benzenesulfonamide analogs and in vitro activity assays yielded a compound that inhibited CAII...
16:16 , Jan 26, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Crystallographic analyses of H. pylori cah bound to sulfonamides could help guide the design of inhibitors to treat H. pylori infection. Comparative crystallographic studies of bacterial cah and human carbonic anhydrase II...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Co-crystal structures of small molecules with carbonic anhydrase IX (CAIX) mimetic and CAII for the design of CAIX-specific compounds

Drug platforms CAIX CAII SignalChem Lifesciences Corp. SLC-0111 Bayer AG Seattle Genetics Inc. anti-CA9 ADC BAY 79-4620 carbonic anhydrase IX (CAIX) University of Florida...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carbonic anhydrase I (CAI); CAII; CAIX; CAXII

Ophthalmic disease INDICATION: Glaucoma In vitro and rabbit studies suggest carbonic anhydrase-inhibiting dendrimers could help treat glaucoma. Chemical synthesis and in vitro testing of poly(amidoamine) (PAMAM)-based dendrimers linked to multiple carbonic anhydrase-inhibiting benzenesulfonamide functional groups...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carbonic anhydrase II (CAII); nitric oxide (NO)

Ophthalmic disease INDICATION: Glaucoma In vitro and animal studies suggest an NO-donating analog of the CAII inhibitor brinzolamide could help treat glaucoma by reducing intraocular pressure (IOP). Brinzolamide reduces aqueous humor production, whereas NO induces...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

Novartis’ Alcon Inc. ophthalmic unit said the European Commission approved an MAA for Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension for whom monotherapy provides an insufficient...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

EMA's CHMP recommended approval of an MAA from Novartis' Alcon Inc. ophthalmic unit for Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy provides...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Identification of small molecule protein inhibitors with laser-assisted detection of specific binding A laser-based system could help identify new small molecule inhibitors of various...